GPN Vaccines Closes Fully Subscribed US$10 Million Private Placement to Advance Gamma-PN™, a Potentially First-in-Class Serotype-Independent Pneumococcal Vaccine
Proceeds to support Phase 2-enabling activities for Gamma-PN, including cGMP manufacturing, expansion of the Company's OPA-testing capabilities and planned submission of an IND to the FDA NEW YORK and ADELAIDE, Australia, Nov. 2, 2026 /PRNewswire/ -- GPN Vaccines, Inc., a clinical-stage...
Covered in this story
Analyst targets on Global Payments
- KeyBanc Capital Markets: $84.6 → $105 by Oct 2027 · Overweight via Investing.com
- Cantor Fitzgerald: $86.1 → $91 by Aug 2027 · Neutral via Investing.com
- Morgan Stanley: $82.4 → $100 by Jul 2027 · Overweight via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $GPN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Global Payments →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.